Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap

Patient Input Requested for AbbVie 2D-GT4 Combo

HepCBC is seeking individual patient input for our submission to the federal government for the first INTERFERON-FREE drug combo for GENOTYPE 4, AbbVie's "2D-GT4".ADD YOUR VOICE! We will be accepting input from anyone affected by hepatitis C (ALL GENOTYPES, not only Genotype 4) between Friday, Sept. 11 and midnight on Thursday, Sept. 25, 2015 through this confidential online form: PATIENT INPUT FORM for AbbVie 2D-GT4 Free WEBINAR about AbbVie 2D-GT4 availa

SOVALDI Webinar slides – Link to Dr Ramji July 3 presentation

Link to July 3, 2014 WEBINAR about Sovaldi by Dr. Alnoor Ramji, co-hosted by HepCBC and the Pacific Hepatitis C Network. You just need to type in your name, email, etc. - no PW required. This webinar will only be online through July 14, 2014. To submit your voice to the Sovaldi (sofosbuvir) heptitis C drug review, please go to this page: http://hepcbc.ca/2014/07/sovaldi-bc/ . Sovaldi is produced by Gilead Sciences.

New COMBO hepatitis C treatment from AbbVie – new factsheet

HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from AbbVie for genotype 1. Note this treatment is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_AbbVie.pdf

Sofosbuvir and Ledipasvir, a new COMBO Hepatitis C treatment

HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from Gilead, sofosbuvir (SOVALDI) and ledipasvir for genotype 1 only.  Note ledipasvir alone, or in this or any other combination, is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_SOF-LDV.pdf